Association between hypothyroidism and risk of chronic kidney disease: evidence from a systematic review and meta-analysis

Background: Chronic kidney disease (CKD) has become a significant issue in global public health, with its prevalence showing a persistent upward trend. Traditional risk factors cannot fully explain the persistent increase in incidence rates. Hypothyroidism, a common endocrine disorder, is considered a potential non-traditional risk factor for CKD, but the evidence remains inconsistent. This study aims to systematically evaluate the association between hypothyroidism and CKD risk.

Methods: Search PubMed, Embase, Web of Science, and Cochrane Library databases for relevant literature up to September 1, 2025. Included observational studies reporting the association between overt or subclinical hypothyroidism and CKD risk, providing odds ratios (OR) or hazard ratios (HR) with 95% confidence intervals (CIs). Quality assessment was conducted using the Newcastle–Ottawa Scale (NOS) and the Agency for Healthcare Research and Quality (AHRQ) quality assessment tool. Calculate pooled risk estimates using random-effects models, and conduct subgroup analyses, sensitivity analyses, and publication bias analyses.

Results: A total of 13 publications reporting 15 studies (11 cross-sectional and 4 cohort studies) involving approximately 5,101,102 participants were included. The pooled analysis of cross-sectional studies demonstrated that hypothyroidism was significantly associated with CKD (OR = 1.66, 95% CI: 1.43–1.94; I² = 78.6%). Subgroup analyses revealed consistent associations across different thyroid disease types, regions, diagnostic methods, and study quality group. Pooled results from cohort studies also demonstrated that hypothyroidism significantly increased CKD risk (HR = 1.21, 95% CI 1.08-1.36; I² = 50.08%). Sensitivity analysis results remained stable. Publication bias was present in cross-sectional studies, but the association remained significant after using the trim-and-fill method (adjusted OR = 1.29, 95% CI: 1.06–1.57).

Conclusion: This systematic review and meta-analysis suggests that hypothyroidism is associated with an increased risk of CKD. Future well-designed prospective and interventional studies are needed to clarify temporal and causal relationships and to elucidate the underlying mechanisms between hypothyroidism and renal dysfunction.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251143834.

Introduction

Chronic kidney disease (CKD), defined as persistent structural or functional kidney abnormalities lasting at least three months and leading to health complications (1), has become a growing global public health challenge. In 2017, an estimated 697.5 million people worldwide were affected across all stages of CKD (95% uncertainty interval: 649.2–752.0 million), corresponding to a prevalence of 9.1% (8.5%–9.8%), with an increasing trend (2). This high prevalence underscores the urgent need for more effective prevention strategies. Previous studies have identified key risk factors for CKD, including age, hypertension, diabetes, obesity, proteinuria, dyslipidemia, and salt intake (3). However, these known factors cannot fully explain the persistent rise in CKD incidence. Increasing evidence suggests that non-traditional systemic factors, particularly endocrine and metabolic dysregulation, may play a significant role in the onset and progression of CKD (4, 5). Given the close physiological interactions between thyroid hormones and renal hemodynamics, glomerular filtration, and tubular function, thyroid dysfunction is increasingly recognized as a potential factor contributing to the onset and progression of CKD.

Hypothyroidism is a common thyroid dysfunction. Overt hypothyroidism is characterized by thyroid-stimulating hormone (TSH) levels above the reference range and free thyroxine (FT4) levels below the reference range, whereas subclinical hypothyroidism presents with elevated TSH but normal FT4 levels (6). Recent large-scale population-based data indicate that the prevalence of hypothyroidism has shown a continuous upward trend over the past decade. A study by Wyne et al. (7) found that the overall prevalence of hypothyroidism in the United States increased from approximately 9.5% in 2012 to 11.7% in 2019, with subclinical hypothyroidism showing particularly marked growth. Hypothyroidism is more common in women and the elderly, and its systemic effects extend far beyond metabolic regulation. Given the high prevalence of hypothyroidism and its extensive physiological impact, increasing attention is being directed toward the potential effects of hypothyroidism on dysfunction in organ systems beyond the thyroid itself, particularly those systems highly sensitive to hemodynamic and hormonal regulation.

Among these organ systems outside the thyroid, the kidneys are particularly susceptible to changes in thyroid hormone status. Thyroid hormones can influence renal function by indirectly affecting cardiac output and renal blood flow changes, or by directly influencing glomerular filtration rate, tubular secretion and reabsorption, and electrolyte balance (8, 9). Recent evidence indicates that individuals with hypothyroidism exhibit a higher incidence of CKD compared to the general population (8, 10, 11). Moreover, compared with CKD patients with normal thyroid function, those with hypothyroidism exhibit poorer renal outcomes and a higher risk of progression to end-stage renal disease and mortality (10, 12, 13). Nevertheless, the results across different studies are not entirely consistent. A large cohort study involving 4,152,830 patients found that individuals with hypothyroidism had a 25% higher risk of developing CKD compared to those with normal thyroid function (14). Additionally, a previous meta-analysis of diabetic populations reported a significant association between hypothyroidism and CKD risk (OR 1.22; 95% CI 1.10–1.36), further supporting the potential link between thyroid dysfunction and renal outcomes despite its findings being limited to diabetic patients (15). However, a cohort study involving 11,872 patients found that the association between hypothyroidism and CKD risk was not statistically significant (HR = 1.01, 95% CI 0.83–1.21) (16). These inconsistent findings highlight the need for a comprehensive evaluation of the relationship between hypothyroidism and CKD risk.

Previous meta-analyses have only examined the relationship between subclinical hypothyroidism and the risk of CKD, or have been limited to specific populations (diabetic individuals) (15), and the number of included studies was limited (17). To address this research gap, we conducted a systematic review and meta-analysis to comprehensively evaluate the association between hypothyroidism (including overt and subclinical forms) and CKD risk. By integrating data from diverse populations, this study aims to provide more generalizable evidence regarding the association between hypothyroidism and CKD risk.

Methods

Registration of review protocol

This study was reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and was prospectively registered in PROSPERO (registration number: CRD420251143834).

Search strategy

Two researchers (X.Y.H. and Y.J.A.) independently retrieved publications from the Web of Science, PubMed, Cochrane Library, and EMBASE databases from their inception through September 1, 2025. The search terms for this study combined Medical Subject Headings (MeSH) with free-text terms, including: “hypothyroidism” or “subclinical hypothyroidism” or “thyroid dysfunction” or “thyroid insufficiency” and “chronic kidney disease” or “renal insufficiency” or “chronic renal insufficiency” or “kidney insufficiency”. We considered only studies written in English and based on human subjects. To identify potentially eligible articles, we also searched and read the full references from original studies. For detailed search strategies, details are provided in Supplementary Table 1.

Study selection

The inclusion criteria for this meta-analysis are as follows (1): Observational studies (cross-sectional, cohort, or case-control studies) examining the association between hypothyroidism and the risk of CKD (2). Complete data were reported, including odds ratio (OR) or hazard ratio (HR), along with 95% confidence intervals (CIs). (3) Published in English. (4) The research is based on human subjects. (5) The diagnosis of hypothyroidism is based on measurements of TSH and FT4 concentrations or on self-reported medical history, along with the use of levothyroxine replacement therapy.

The exclusion criteria for this meta-analysis are as follows: (1) conference abstracts, case reports, reviews, practice guidelines, commentaries, or editorials; (2) Studies examining the association between serum TSH levels or thyroid hormone levels and CKD risk. (3) Studies involving only individuals with normal thyroid function; (4) Studies were not included if they did not report a dichotomous CKD outcome based on eGFR <60 mL/min/1.73 m² and only analyzed continuous changes in eGFR.

CKD definition

CKD was predefined as the primary outcome. CKD was defined as including an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m², with or without renal injury markers such as proteinuria or albuminuria. Studies were eligible if CKD was determined through laboratory measurements (eGFR derived from serum creatinine), regardless of the specific equation used (MDRD or CKD-EPI) (18, 19). Studies defining CKD solely based on self-report without biochemical confirmation were excluded.

Data extraction and quality assessment

Two researchers (X.Y.H. and Y.J.A.) independently extracted and cross-checked data from studies ultimately included in the meta-analysis. Any disagreements between researchers regarding the inclusion of eligible studies were resolved through consensus and consultation with a third researcher (D.L.L.). We extracted the following data from each study: publication year, country, study design, sample size, mean age, male proportion, follow-up duration, diagnostic methods for hypothyroidism and CKD, type of thyroid disease, and matched and confounding factors adjusted for in multivariate regression analysis.

Two researchers conducted quality assessments of cohort studies using the Newcastle-Ottawa Scale (NOS) and of cross-sectional studies using the Agency for Healthcare Research and Quality (AHRQ) criteria (20). Studies scoring below 5 points are rated as low quality, those scoring 5–7 points are rated as moderate quality, and studies scoring 8 points or above were rated as high quality. All disagreements were resolved through mutual agreement and discussion with another author.

Statistical analyses

We used OR from cross-sectional studies and HR from longitudinal studies as effect sizes (ES), each with 95% confidence intervals. When studies reported OR/HR values with varying degrees of covariate adjustment, we selected the OR/HR that most fully reflected the potential confounding variables.

The statistical heterogeneity of each study was assessed using the I² statistic. A random-effects model was applied when heterogeneity was substantial (I² ≥ 50%), whereas a fixed-effect model was used when heterogeneity was low to moderate (I² < 50%). The I² statistic is classified into low heterogeneity (<25%), moderate heterogeneity (25%-75%), and high heterogeneity(>75%) (21). To explore potential sources of heterogeneity among studies and assess the robustness of findings, subgroup analyses were conducted based on region, type of thyroid disease, thyroid diagnostic method, and risk of bias. To assess the robustness of the results, we employed a leave-one-out analysis to examine potential over-influence from individual studies (22). Potential publication bias was analyzed using funnel plots and the Egger’s test when ≥10 studies were available (23), and further explored using the Duval and Tweedie nonparametric trim-and-fill methods (24).

All statistical tests in this study were two-tailed, with P < 0.05 considered statistically significant. Statistical analysis was performed using R software (version 4.3.2; packages ‘meta’ and ‘metafor’).

Results

Literature search

Figure 1 presents the flowchart of the literature screening process. A systematic search of studies published before September 1, 2025 yielded a total of 2,572 results. After initial screening, 1,243 duplicate records were excluded. Additionally, based on title and abstract screening, 1,261 articles were excluded for irrelevance to the study topic. The remaining 68 studies underwent full-text review. A total of 13 publications reporting 15 studies (11 cross-sectional and 4 cohort studies), with some publications reporting multiple studies. These studies reported on the relationship between hypothyroidism and CKD risk.

Figure 1

Figure 1. Flow chart of study selection of hypothyroidism in relation to CKD.

Study characteristics

A total of 13 publications reporting 15 studies published between 2011 and 2024 were included in this meta-analysis, comprising 11 cross-sectional studies and 4 cohort studies (10, 13, 14, 16, 25–33), with a combined sample size of 5,101,102 participants. In terms of the study population, 8 studies were conducted on people of all ages, and 2 studies were conducted on people with diabetes. The relationship between subclinical hypothyroidism and CKD was discussed in 4 studies, while the relationship between hypothyroidism and CKD was discussed in 10 studies, and 1 study did not specify whether it was hypothyroidism or subclinical hypothyroidism. In all 15 included studies, CKD was defined using an eGFR threshold <60 mL/min/1.73 m², with 5 studies additionally incorporating criteria for proteinuria or albuminuria. Among cross-sectional studies, 10 studies determined CKD based on a single eGFR measurement, while 1 study used multiple measurements. Among the cohort studies, 4 studies used repeated eGFR measurements or predefined longitudinal algorithms during follow-up to determine CKD or event-driven CKD. All studies based CKD determination on laboratory measurements, none relied solely on diagnostic codes or self-reported CKD. In terms of research regions, there were 3 studies in the United States, 3 studies each in China and Japan, and 1 study each in South Korea, Australia, South Africa, Brazil, and Norway. Although the potential confounding factors adjusted for (e.g., age, gender, ethnicity, smoking) varied across studies, all included studies used adjusted effect values. Table 1 shows the main characteristics of the included studies.

Table 1

Table 1. Characteristics of the studies included in the quantitative and qualitative review.

Quality assessment

The NOS scale and AHRQ scale are used for quality assessment in cohort studies and cross-sectional studies, respectively. The average quality score for the 15 studies was 8 points, with 12 studies scoring 8 points or higher. The scores for each study are shown in Table 1, and the scoring criteria for each study are shown in Supplementary Table 2-Supplementary Table 3.

Cross-sectional study of hypothyroidism and CKD risk

Eleven cross-sectional studies analyzed the relationship between hypothyroidism and the risk of CKD. These studies included a total of 514,246 participants, with eight studies scoring 8 points or higher on the AHRQ score and three studies scoring below 8 points, indicating overall moderate to high quality with a generally low risk of bias.

The meta-analysis of cross-sectional studies on hypothyroidism and the risk of CKD is shown in Figure 2. Due to the high degree of heterogeneity (I² = 78.59%), we applied a random-effects model for analysis. The combined analysis of 11 cross-sectional studies revealed a significant positive association between hypothyroidism and the risk of CKD (pooled random-effects OR = 1.66, 95% CI 1.43-1.94; I² = 78.59%, P<0.01). Since we used fully adjusted estimates, the pooled random effects OR values were independent of risk factors such as age, gender, ethnicity, smoking, and diabetes.

Figure 2

Figure 2. Forest plot of cross-sectional studies on the association between hypothyroidism and CKD risk.

Subgroup analysis of cross-sectional studies

To further explore potential sources of heterogeneity and validate the stability of results, we conducted several subgroup analyses. Subgroup analyses were conducted based on cross-sectional studies due to the small number of studies included in the cohort study and all of them were overt hypothyroidism population. As shown in Supplementary Figure 1, a stratified comparison was performed according to the type of hypothyroidism. A total of 7 studies included hypothyroid populations and 4 studies included subclinical hypothyroid populations. Hypothyroidism was significantly positively associated with CKD risk in both groups. The hypothyroidism group showed a lower random-effects OR and higher heterogeneity (n=7 studies, OR = 1.59, 95% CI 1.32-1.92; I² = 79.02%, P<0.01), suggesting that the heterogeneity in the meta-analysis may originate from within the hypothyroidism group.

Subgroup analysis of the study by region showed that the association between hypothyroidism and CKD risk was consistent across different regions. There were 5 studies from the Asian region and 6 from the non-Asian region. As shown in Supplementary Figure 2, the random-effects OR values were lower in non-Asian regions and showed significant heterogeneity (n=6 studies, OR = 1.54, 95% CI 1.25-1.89; I² = 69.46%, P<0.01).

Subgroup analysis based on the diagnostic methods for hypothyroidism showed that there was still a significant positive correlation between hypothyroidism and CKD risk in both the TSH-based diagnosis group and the TSH and FT4-based diagnosis group. A total of 3 studies diagnosed on the basis of TSH and 8 studies diagnosed on the basis of TSH+FT4. As shown in Supplementary Figure 3, the group diagnosed using TSH showed a significant association, but there was extremely high heterogeneity (n=3 studies, OR = 1.66, 95% CI 1.18-2.35; I² = 91.60%, P<0.01).

Subgroup analysis of studies based on bias risk showed that the positive association between hypothyroidism and CKD risk remained significant in studies with low bias risk and in the moderate bias risk group. There were 3 medium-quality studies and 8 high-quality studies. As shown in Supplementary Figure 4, the low bias risk group has high heterogeneity, but the combined effect value is stable (n=8 studies, OR = 1.69, 95% CI 1.42-2.01; I² = 83.04%, P<0.01).

Cohort study of hypothyroidism and CKD risk

Three studies analyzed the relationship between overt hypothyroidism and CKD, and one study analyzed the relationship between hypothyroidism (unable to determine whether it was overt or subclinical hypothyroidism) and CKD. These studies included a total of 4,586,856 participants, with a median follow-up time ranging from 3 to 19.6 years. Three studies had a NOS score of 8, and one study had a score of 9, indicating a low risk of bias.

Due to moderate heterogeneity (I² = 50.08%), a random effects model was used for the analysis. As shown in Figure 3, the results of the meta-analysis of cohort studies found a significant positive correlation between hypothyroidism and the risk of CKD (HR = 1.21, 95% CI 1.08-1.36; I² = 50.08%). This combined effect is independent of common risk factors such as age, gender, ethnicity, and hypertension.

Figure 3

Figure 3. Forest plot of cohort studies on the association between hypothyroidism and CKD risk.

Sensitivity analysis

Sensitivity analyses were conducted to explore potential sources of heterogeneity between hypothyroidism and CKD risk and to validate the stability of our findings. In the exclusion analyses where one study was sequentially omitted, the overall risk estimate from cross-sectional studies did not show significant changes, with the pooled estimates of hypothyroidism and CKD risk ranging from 1.62 (95% CI: 1.39–1.93) to 1.83 (95% CI: 1.63–2.05). The sensitivity analysis results of the cross-sectional study are presented in Supplementary Figure 5. For cohort studies, exclusion analyses under the random-effects model indicated that the direction of pooled effect estimates remained consistent across all scenarios, with HR ranging from 1.19 (95% CI: 1.05–1.35) to 1.25 (95% CI: 1.23–1.27). In some cases, excluding individual studies led to widened confidence intervals and reduced statistical significance. This phenomenon can be explained by the small number of included cohort studies and the reduced precision after excluding influential datasets. Importantly, the direction of association remained unchanged across all analyses, supporting the robustness of the observed relationship. Results of sensitivity analyses for cohort studies are presented in Supplementary Figure 6.

Overall, sensitivity analyses indicate that the direction of the pooled effect is generally consistent. However, the precision of the pooled estimate is somewhat compromised due to the limited number of cohort studies and the presence of influential datasets.

Publication bias

To explore potential publication bias, funnel plots were constructed separately for cross-sectional studies and cohort studies, as shown in Figure 4. The funnel plot of the cross-sectional study exhibits pronounced asymmetry. Egger’s test confirmed the presence of publication bias (P<0.05). Trim-and-fill methods were applied under a random-effects model, interpolating six hypothetical studies. After adjustment, the pooled effect size for cross-sectional studies decreased from OR = 1.66 (95% CI: 1.43-1.94) to OR = 1.29 (95% CI: 1.06-1.57), remaining statistically significant (P = 0.0125). Although the association between the two remained statistically significant after adjustment, the reduced effect size suggests that publication bias may have inflated the strength of the link. Therefore, caution should be exercised when interpreting the study findings.

Figure 4

Figure 4. Funnel plots of publication bias.

Discussion

This meta-analysis included 11 cross-sectional studies and 4 cohort studies, synthesizing data from approximately 5.10 million individuals across different countries, thereby providing substantial evidence. Our findings indicate that hypothyroidism is significantly associated with an increased risk of CKD, both in cross-sectional (OR = 1.66, 95% CI 1.43–1.94) and cohort studies (HR = 1.21, 95% CI 1.08-1.36). When conducting subgroup analyses based on thyroid disease type, region, diagnostic methods for hypothyroidism, and risk of bias, the positive association between hypothyroidism and CKD risk remained consistent across different subgroups. However, some subgroups included a small number of studies and the results should be interpreted with caution. Publication bias was present in the cross-sectional studies, but the association persisted after adjustment using trim-and-fill methods, indicating the stability of the results. This large-scale, comprehensive meta-analysis provides a thorough description of the strong association between hypothyroidism and CKD.

Our research has found that hypothyroidism is positively associated with the risk of CKD. Consistent with our findings, the meta-analysis by Meuwese et al. (34) demonstrated a cross-sectional correlation between hypothyroidism and reduced eGFR levels compared with participants with normal thyroid function, although an accelerated decline in renal function was not observed in the longitudinal analysis. Furthermore, a previous meta-analysis of diabetic populations demonstrated that hypothyroidism is significantly associated with an increased risk of CKD, providing further support for the link between thyroid dysfunction and adverse renal outcomes (15). Our findings expand upon and complement the conclusions of previous meta-analyses. Wang et al. (17) reported that subclinical hypothyroidism is significantly associated with an increased risk of CKD, although the number of included studies was limited. This study integrated evidence from 15 observational studies involving approximately 5.10 million participants, significantly enhancing the statistical power and reliability of the pooled estimates. Furthermore, although the study by Wang et al. (17) primarily emphasized the impact of subclinical hypothyroidism on CKD risk, our findings indicate that both overt and subclinical hypothyroidism increase CKD risk. This association remains robust across subgroups stratified by region, diagnostic method, and risk of bias. Compared with previous studies, this research provides a more comprehensive and updated quantitative assessment of the association between hypothyroidism and CKD across diverse populations.

Evidence from Mendelian randomization (MR) studies further discusses the causal relationship between hypothyroidism and CKD. Ellervik et al. (35) and Tsao et al. (36) reported that genetically predicted elevated levels of TSH were causally associated with hyponephrosis, which supports the direction of the association observed in our analysis. In contrast, a bidirectional MR study by Xu et al. (11) suggests that chronic renal failure may have a causal effect on hypothyroidism, rather than the other way around. These findings highlight the complexity of thyroid-kidney interactions and emphasize the need for caution in interpreting causal relationships.

Hypothyroidism is positively associated with the risk of CKD, and thyroid dysfunction and CKD exhibit a bidirectional relationship, with potential mechanisms involving multiple pathways (37, 38). A cross-sectional study involving 91 CKD patients revealed a high prevalence of hypothyroidism at 30.8% among CKD patients (39). Furthermore, a significant association was observed between chronic kidney disease stages and thyroid dysfunction, supporting this bidirectional concept. Hypothyroidism adversely affects kidney structure and function through multiple pathways. Animal studies have revealed that hypothyroidism leads to a decrease in the kidney-to-body weight ratio in rats, alterations in the glomerular basement membrane, and increased permeability of glomerular capillaries (40–42). Hypothyroidism-induced renal impairment may be explained by the following mechanisms (1): reduced renin-angiotensin-aldosterone system activity leading to inadequate glomerular perfusion and water-sodium retention; (2) decreased cardiac output resulting in reduced renal blood flow; (3) elevated chronic low-grade inflammation and oxidative stress accelerating glomerulosclerosis (8, 9, 41, 43, 44). Hypothyroidism may also cause electrolyte disturbances, leading to hyponatremia and impaired urinary concentrating ability. Long-term effects may impair renal tubulointerstitial function (44–46). Recent studies have found that levothyroxine therapy for hypothyroidism can improve renal function in patients and even reverse CKD status, suggesting a close relationship between hypothyroidism and CKD (47–49). Our findings provide further evidence for the association between hypothyroidism and CKD risk, though the specific mechanisms involved warrant further investigation in future studies.

This study adds to the existing body of research by incorporating more recent evidence and updating previous findings. It not only examines the impact of subclinical hypothyroidism on CKD risk but also addresses the effects of overt hypothyroidism, thereby providing more comprehensive evidence. Second, this study incorporated research from a wider range of regions, thereby enhancing the generalizability of the findings. Finally, this study incorporated both prospective cohort studies and cross-sectional studies, thereby mitigating the effects of recall bias and selection bias while overcoming the limitation of cross-sectional studies in drawing causal inferences. Notably, the association observed in cross-sectional studies was stronger (pooled OR = 1.66), whereas the association in cohort studies was relatively weaker (pooled HR = 1.21). This discrepancy arises because cross-sectional studies reflect prevalence-based associations susceptible to reverse causality and residual confounding, whereas cohort studies provide time-to-event risk estimates that better capture temporal order between exposure and outcome. Thus, the relatively attenuated effect size in cohort studies offers more conservative and time-based evidence for the association between hypothyroidism and subsequent CKD risk.

This meta-analysis also has certain limitations. First, the small number of cohort studies included and the fact that the overall evidence comes mainly from cross-sectional studies limits the strength of causal inferences. Although cohort studies provide time-based evidence, the limited number of such studies calls for caution in interpreting the results of longitudinal studies. Second, although we collected the most fully adjusted risk estimates, each study adjusted for different confounding factors, and residual confounding from unmeasured factors cannot be entirely ruled out, which may affect the association between hypothyroidism and CKD risk. Variations in measurement standards and methods for hypothyroidism may affect the accuracy of our results. Although we analyzed the impact of different diagnostic approaches on outcomes in subgroup analyses, we cannot entirely rule out potential biases arising from measurement techniques and standards. As well, although the definition of CKD was standardized using a threshold of eGFR <60 mL/min/1.73 m². Differences in outcome determination, however, including single versus repeated eGFR measurements and the selective use of albuminuria, may be a source of residual heterogeneity that could not be fully addressed in the meta-analysis. Third, substantial heterogeneity was found in several of the pooled analyses, reflecting differences in study design, population characteristics, exposure definitions, and outcome determination. This heterogeneity may affect the precision of the pooled estimates and should be taken into account when interpreting the pooled results. Fourth, we identified publication bias in the meta-analysis of cross-sectional studies. Although bias was corrected using trim-and-fill methods and results were confirmed to be stable, caution is warranted when interpreting these findings. Small-scale negative studies may be underrepresented, and the true effect size may be smaller than initially observed. Fifth, since only English-language publications were included, relevant studies published in other languages may have been omitted, potentially introducing language bias. Furthermore, given the bidirectional relationship between thyroid dysfunction and chronic kidney disease, the possibility of reverse causality cannot be entirely ruled out. Although mechanistic studies and cohort studies provide some support for a temporal association between hypothyroidism and subsequent CKD risk, reverse causality remains impossible to completely exclude in cross-sectional studies. Finally, a large cohort study (You et al., 2024) (14) represents a large proportion of the overall sample and thus greatly affects the precision of the pooled effect estimates as well as the combined effect values, so the results of cohort studies should be interpreted with caution. Sensitivity analyses revealed that excluding this study resulted in wider confidence intervals and reduced statistical significance, yet the direction of association between hypothyroidism and CKD risk remained consistent. Given these limitations, well-designed prospective and interventional studies are necessary to further elucidate the temporal relationship and underlying mechanisms between hypothyroidism and CKD.

Conclusion

In summary, this comprehensive meta-analysis provides substantial evidence for a significant and independent positive correlation between hypothyroidism and the risk of CKD. This association persisted and remained stable across different thyroid disease categories, geographic regions, diagnostic methods, and study quality. Given the rising prevalence and disease burden of CKD worldwide, early identification of thyroid dysfunction may have potential implications for CKD prevention, but its clinical impact remains to be clarified in future prospective studies.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

W-KZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Writing – original draft, Writing – review & editing. X-YH: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing. Y-JA: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Writing – original draft. D-LL: Conceptualization, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing. H-LL: Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the National Natural Science Foundation of China (Grant no. 82274419), the Basic and Applied Basic Research Foundation of Guangdong Province (Grant no. 2021A1515220177), and the Sanming Project of Medicine in Shenzhen (Grant no. SZZYSM202411016).

Acknowledgments

We thank all the authors of the studies included in our meta-analysis.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2026.1704228/full#supplementary-material

References

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. (2024) 105:S117–314. doi: 10.1016/j.kint.2023.10.018

PubMed Abstract | Crossref Full Text | Google Scholar

2. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2020) 395:709–33. doi: 10.1016/S0140-6736(20)30045-3

PubMed Abstract | Crossref Full Text | Google Scholar

3. Mallamaci F and Tripepi G. Risk factors of chronic kidney disease progression: between old and new concepts. J Clin Med. (2024) 13:678. doi: 10.3390/jcm13030678

PubMed Abstract | Crossref Full Text | Google Scholar

4. Yin Y, Zhao C, Hua Y, Yang F, Qiu D, Yan J, et al. Exploring the common genetic basis of metabolic syndrome-related diseases and chronic kidney disease: insights from extensive genome-wide cross-trait analyses. BioData Min. (2025) 18:54. doi: 10.1186/s13040-025-00472-7

PubMed Abstract | Crossref Full Text | Google Scholar

5. Xu X, Shao X, and Hou FF. Risk stratification of metabolic disorder–associated kidney disease. Kidney Int. (2025) 107:1002–10. doi: 10.1016/j.kint.2025.01.041

PubMed Abstract | Crossref Full Text | Google Scholar

6. Chaker L, Bianco AC, Jonklaas J, and Peeters RP. Hypothyroidism. Lancet. (2017) 390:1550–62. doi: 10.1016/S0140-6736(17)30703-1

PubMed Abstract | Crossref Full Text | Google Scholar

7. Wyne KL, Nair L, Schneiderman CP, Pinsky B, Antunez Flores O, Guo D, et al. Hypothyroidism prevalence in the United States: A retrospective study combining national health and nutrition examination survey and claims data, 2009–2019. J Endocr Soc. (2023) 7:bvac172. doi: 10.1210/jendso/bvac172

PubMed Abstract | Crossref Full Text | Google Scholar

8. Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinology Diabetes Obes. (2016) 23:407. doi: 10.1097/MED.0000000000000275

PubMed Abstract | Crossref Full Text | Google Scholar

9. Spahia N, Rroji M, Barbullushi M, and Spasovski G. Subclinical hypothyroidism, kidney, and heart from normal to uremic milieu. Metab Syndrome Related Disord. (2023) 21:415–25. doi: 10.1089/met.2023.0057

PubMed Abstract | Crossref Full Text | Google Scholar

10. Huang C-W, Li BH, Reynolds K, Jacobsen SJ, Rhee CM, and Sim JJ. Association between hypothyroidism and chronic kidney disease observed among an adult population 55 years and older. Med (Baltimore). (2020) 99:e19569. doi: 10.1097/MD.0000000000019569

PubMed Abstract | Crossref Full Text | Google Scholar

11. Xu Y, Wang X, Wang G, Wei W, and Li N. Relationship between hypothyroidism and chronic kidney disease: Results from the National Health and Nutrition Examination Survey 2007 to 2012 and Mendelian randomization study. Medicine. (2024) 103:e40925. doi: 10.1097/MD.0000000000040925

PubMed Abstract | Crossref Full Text | Google Scholar

12. Schultheiss UT, Steinbrenner I, Nauck M, Schneider MP, Kotsis F, Baid-Agrawal S, et al. Thyroid function, renal events and mortality in chronic kidney disease patients: the German Chronic Kidney Disease study. Clin Kidney J. (2021) 14:959–68. doi: 10.1093/ckj/sfaa052

PubMed Abstract | Crossref Full Text | Google Scholar

13. Chang Y-C, Chang CH, Yeh Y-C, Chuang L-M, and Tu Y-K. Subclinical and overt hypothyroidism is associated with reduced glomerular filtration rate and proteinuria: a large cross-sectional population study. Sci Rep. (2018) 8:2031. doi: 10.1038/s41598-018-19693-4

PubMed Abstract | Crossref Full Text | Google Scholar

14. You AS, Kalantar-Zadeh K, Brent GA, Narasaki Y, Daza A, Sim JJ, et al. Impact of thyroid status on incident kidney dysfunction and chronic kidney disease progression in a nationally representative cohort. Mayo Clinic Proc. (2024) 99:39–56. doi: 10.1016/j.mayocp.2023.08.028

PubMed Abstract | Crossref Full Text | Google Scholar

15. Zhang S, Feng G, Kang F, Guo Y, Ti H, Hao L, et al. Hypothyroidism and adverse endpoints in diabetic patients: A systematic review and meta-analysis. Front Endocrinol (Lausanne). (2019) 10:889. doi: 10.3389/fendo.2019.00889

PubMed Abstract | Crossref Full Text | Google Scholar

16. Schultheiss UT, Daya N, Grams ME, Seufert J, Steffes M, Coresh J, et al. Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant. (2017) 32:1874–81. doi: 10.1093/ndt/gfw301

PubMed Abstract | Crossref Full Text | Google Scholar

17. Wang X, Zhao X, and Huang X. Association of subclinical thyroid dysfunction with chronic kidney disease: A systematic review and meta-analysis. Endocrine Res. (2020) 45:41–9. doi: 10.1080/07435800.2019.1645164

PubMed Abstract | Crossref Full Text | Google Scholar

18. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:604–12. doi: 10.7326/0003-4819-150-9-200905050-00006

PubMed Abstract | Crossref Full Text | Google Scholar

19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. . Ann Intern Med. (1999) 130:461–70. doi: 10.7326/0003-4819-130-6-199903160-00002

PubMed Abstract | Crossref Full Text | Google Scholar

20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z

PubMed Abstract | Crossref Full Text | Google Scholar

21. Higgins JPT and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. doi: 10.1002/sim.1186

PubMed Abstract | Crossref Full Text | Google Scholar

22. Wallace BC, Schmid CH, Lau J, and Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. (2009) 9:80. doi: 10.1186/1471-2288-9-80

PubMed Abstract | Crossref Full Text | Google Scholar

23. Egger M, Davey Smith G, Schneider M, and Minder C. Bias in meta-analysis detected by a simple, graphical test. . BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

PubMed Abstract | Crossref Full Text | Google Scholar

24. Duval S and Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. (2000) 56:455–63. doi: 10.1111/j.0006-341x.2000.00455.x

PubMed Abstract | Crossref Full Text | Google Scholar

25. Kim HJ, Park SJ, Park HK, Byun DW, Suh K, and Yoo MH. Subclinical thyroid dysfunction and chronic kidney disease: a nationwide population-based study. BMC Nephrol. (2023) 24:64. doi: 10.1186/s12882-023-03111-7

PubMed Abstract | Crossref Full Text | Google Scholar

26. Shimizu Y, Kawashiri S-Y, Noguchi Y, Nakamichi S, Nagata Y, Hayashida N, et al. Associations among ratio of free triiodothyronine to free thyroxine, chronic kidney disease, and subclinical hypothyroidism. J Clin Med. (2022) 11:1269. doi: 10.3390/jcm11051269

PubMed Abstract | Crossref Full Text | Google Scholar

27. Johnson L and Rayner B. A cross-sectional cohort study with microvascular complications in patients with type 2 diabetes with and without hypothyroidism. Cardiovasc J Afr. (2020) 31:5–8. doi: 10.5830/CVJA-2019-036

PubMed Abstract | Crossref Full Text | Google Scholar

28. Toda A, Hara S, Kato M, Tsuji H, and Arase Y. Association of thyrotropin concentration with chronic kidney disease in a Japanese general population cohort. Nephron. (2019) 142:91–7. doi: 10.1159/000497326

PubMed Abstract | Crossref Full Text | Google Scholar

29. Peixoto De Miranda ÉJF, Bittencourt MS, Goulart AC, Santos IS, De Oliveira Titan SM, Ladeira RM, et al. Thyrotropin levels are associated with chronic kidney disease among healthy subjects in cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Clin Exp Nephrol. (2017) 21:1035–43. doi: 10.1007/s10157-017-1400-2

PubMed Abstract | Crossref Full Text | Google Scholar

30. Chuang M, Liao K-M, Hung Y-M, Wang PY-P, Chou Y-C, and Chou P. Abnormal thyroid-stimulating hormone and chronic kidney disease in elderly adults in taipei city. J Am Geriatrics Soc. (2016) 64:1267–73. doi: 10.1111/jgs.14102

PubMed Abstract | Crossref Full Text | Google Scholar

31. Jia F, Tian J, Deng F, Yang G, Long M, Cheng W, et al. Subclinical hypothyroidism and the associations with macrovascular complications and chronic kidney disease in patients with Type 2 diabetes. Diabetes Med. (2015) 32:1097–103. doi: 10.1111/dme.12724

PubMed Abstract | Crossref Full Text | Google Scholar

32. Gopinath B, Harris DC, Wall JR, Kifley A, and Mitchell P. Relationship between thyroid dysfunction and chronic kidney disease in community-dwelling older adults. Maturitas. (2013) 75:159–64. doi: 10.1016/j.maturitas.2013.03.009

PubMed Abstract | Crossref Full Text | Google Scholar

33. Åsvold BO, Bjøro T, and Vatten LJ. Association of thyroid function with estimated glomerular filtration rate in a population-based study: the HUNT study. Eur J Endocrinol. (2011) 164:101–5. doi: 10.1530/eje-10-0705

PubMed Abstract | Crossref Full Text | Google Scholar

34. Meuwese CL, van Diepen M, Cappola AR, Sarnak MJ, Shlipak MG, Bauer DC, et al. Low thyroid function is not associated with an accelerated deterioration in renal function. Nephrol Dial Transplant. (2019) 34:650–9. doi: 10.1093/ndt/gfy071

PubMed Abstract | Crossref Full Text | Google Scholar

35. Ellervik C, Mora S, Ridker PM, and Chasman DI. on behalf of the CKDGen consortium. Hypothyroidism Kidney Function: A Mendelian Randomization Study. Thyroid. (2020) 30:365–79. doi: 10.1089/thy.2019.0167

PubMed Abstract | Crossref Full Text | Google Scholar

36. Tsao H-M, Shao Y-HJ, Chang Y-C, Chou Y-H, Wu V-C, Lin S-L, et al. Unveiling the causal relationship between thyroid and kidney function: A multivariable mendelian randomization. CJASN. (2025) 20:922–30. doi: 10.2215/CJN.0000000722

PubMed Abstract | Crossref Full Text | Google Scholar

37. Narasaki Y, Sohn P, and Rhee CM. The interplay between thyroid dysfunction and kidney disease. Semin Nephrol. (2021) 41:133–43. doi: 10.1016/j.semnephrol.2021.03.008

PubMed Abstract | Crossref Full Text | Google Scholar

38. Echterdiek F, Ranke MB, Schwenger V, Heemann U, and Latus J. Kidney disease and thyroid dysfunction: the chicken or egg problem. Pediatr Nephrol. (2022) 37:3031–42. doi: 10.1007/s00467-022-05640-z

PubMed Abstract | Crossref Full Text | Google Scholar

39. Soumya PS, Shifa K, and Sanju ST. Study of thyroid function in patients with chronic kidney disease. ijsr. (2025) 14:60–61. doi: 10.36106/ijsr/92078378

Crossref Full Text | Google Scholar

40. Rodríguez-Gómez I, Banegas I, Wangensteen R, Quesada A, Jiménez R, Gómez-Morales M, et al. Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats. J Endocrinol. (2013) 216:43–51. doi: 10.1530/JOE-12-0208

PubMed Abstract | Crossref Full Text | Google Scholar

41. Vargas F, Moreno JM, Rodríguez-Gómez I, Wangensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. (2006) 154:197–212. doi: 10.1530/eje.1.02093

PubMed Abstract | Crossref Full Text | Google Scholar

42. Slotkin TA, Seidler FJ, Kavlock RJ, and Bartolome JV. Thyroid hormone differentially regulates cellular development in neonatal rat heart and kidney. Teratology. (1992) 45:303–12. doi: 10.1002/tera.1420450309

PubMed Abstract | Crossref Full Text | Google Scholar

43. Basu G and Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J Endocrinol Metab. (2012) 16:204–13. doi: 10.4103/2230-8210.93737

PubMed Abstract | Crossref Full Text | Google Scholar

44. Iglesias P, Bajo MA, Selgas R, and Díez JJ. Thyroid dysfunction and kidney disease: An update. Rev Endocr Metab Disord. (2017) 18:131–44. doi: 10.1007/s11154-016-9395-7

PubMed Abstract | Crossref Full Text | Google Scholar

45. Iglesias P and Díez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. (2009) 160:503–15. doi: 10.1530/EJE-08-0837

PubMed Abstract | Crossref Full Text | Google Scholar

46. Van Hoek I and Daminet S. Interactions between thyroid and kidney function in pathological conditions of these organ systems: A review. Gen Comp Endocrinol. (2009) 160:205–15. doi: 10.1016/j.ygcen.2008.12.008

PubMed Abstract | Crossref Full Text | Google Scholar

47. Uchiyama-Matsuoka N, Tsuji K, Uchida HA, Kitamura S, Itoh Y, Nishiyama Y, et al. Masked CKD in hyperthyroidism and reversible CKD status in hypothyroidism. Front Endocrinol (Lausanne). (2022) 13:1048863. doi: 10.3389/fendo.2022.1048863

PubMed Abstract | Crossref Full Text | Google Scholar

48. Jaryal A, Vikrant S, and Sharma A. Hypothyroidism related kidney disease - A report of two cases. Indian J Nephrol. (2025) 35:574–5. doi: 10.25259/IJN_266_2024

PubMed Abstract | Crossref Full Text | Google Scholar

49. Podimon J, Shallam S, Rahim SA, Philip R, Dev DA, and Khadir CA. Reversible renal dysfunction in hypothyroidism - A study on change in glomerular filtration rate and creatine phosphokinase with correction of hypothyroidism. Thyroid Res Pract. (2024) 20:123. doi: 10.4103/trp.trp_7_24

Crossref Full Text | Google Scholar